Risks of more device, drug price cuts loom as French pares down healthcare spending
This article was originally published in Clinica
The French parliament has passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period, €3.5bn of which will affect medicines, and probably medical devices, in the form of selected price cuts.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.